Wockhardt sets up manufacturing facility in Dubai
Wockhardt has set up its first facility in Middle East for manufacturing of NCEs (New Chemical Entities) catering to the global markets through its Dubai arm of its subsidiary Wockhardt Bio AG.
With an aim to grow and further establish their international presence in pharmaceutical manufacturing, Wockhardt recently inaugurated a ‘state-of-the-art’ manufacturing facility for the production and packaging of sterile dry powder injection in Dubai. On approval of the new drug by US FDA, this manufacturing facility will be commissioned for commercial production. Wockhardt Bio AG manufacturing facility is designed to meet standards of various international regulatory agencies and the standards as set by the Local Ministry of Health. The facility meets the needs of Aseptic Dry Powder Injectable manufacturing and filling with a high quality operation. This facility is dedicated to launch its novel New Chemical Entities in the Antibiotics segment to the world from UAE.